Autologous matrix-induced chondrogenesis is an innovative treatment to repair articular cartilage damage. It is a one step process that uses the microfracturing method, which is followed by application of bilayer collagen I/III membrane by partially autologous fibrin glue. Increasing prevalence of bone and joint disorders such as osteoporosis and arthritis, increasing sports-related injuries, and rising demand for minimally-invasive surgery is driving the autologous matrix-induced chondrogenesis market growth.

Autologous Matrix-induced Chondrogenesis Market - Drivers

Increasing number of joint and bone disorders such as osteoporosis and arthritis globally is expected to drive the autologous matrix-induced chondrogenesis market growth during the forecast period. For instance, according to the National Center for Biotechnology Information (NCBI) 2016 report, over 200 million people are suffering from osteoporosis worldwide in 2015. 1 in 3 women over the age of 50 years and 1 in 5 men will experience osteoporosis fractures in their lifetime.

Rising number of surgeries is expected to drive the autologous matrix-induced chondrogenesis market growth during the forecast period. For instance, according to American Academy of Orthopaedic Surgeon (AAOS) 2019 report, around 267,000 knee replacements are performed each year in the U.S.

Autologous Matrix-induced Chondrogenesis Market - Restraints

Inefficient system of reimbursement and high cost of cartilage replacement are major factors restraining growth of the autologous matrix-induced chondrogenesis market. Several health insurance companies do not insure AMIC procedure. For instance, according to Blue Cross Blue Shield of North Carolina 2019, for patients without health insurance, a total hip replacement usually costs between US$ 31,839 and US$ 44,816, with an average cost of US$ 39,299 in the U.S.

Autologous Matrix-induced Chondrogenesis Market - Regional Analysis

On the basis of region, the autologous matrix-induced chondrogenesis market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold dominant position in the autologous matrix-induced chondrogenesis market during the forecast period, owing to increasing sports-related injuries and rising population. For instance, according to National Safety Council (NSC) report, in 2017, over 526,000 sports-related injuries were reported in the U.S.

Asia Pacific is expected to witness significant growth over the forecast period, owing to rising demand for minimally-invasive surgery in the region. For instance, according to the National Center for Biotechnology Information, in 2017, minimally-invasive surgery was carried out firstly in China. Laparoscopy surgery was one of the first types of minimally-invasive surgery.

Autologous Matrix-induced Chondrogenesis Market - Competitive Landscape

Key players operating in the autologous matrix-induced chondrogenesis market include Biotissue AG, Arthro-Kinetics, JRL Orthopaedic Ltd, B Braun, Melsungen AG, Matricel GmbH, Geistlich Pharma AG, and Zimmer Biomet Holdings.

Autologous Matrix-induced Chondrogenesis Market - Taxonomy

The global autologous matrix-induced chondrogenesis market is segmented on the basis of material type, application, and region.

By Material Type